RayKnowChina Research Map
Shortlist

RecruitingLymphomaPhase 1

Registered title, quoted from ClinicalTrials.gov

Exploration of Circular RNA in B-cell Hematologic Malignancies

An open trial on lymphoma, registered on ClinicalTrials.gov. Led by Ruijin Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorRuijin Hospital上海交通大学医学院附属瑞金医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07774572, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. ECOG performance status 0 or 1.and have archival tumor biopsy tissue and pathology report from the most recent relapse, or at least one palpable superficial tumor lesion at screening, and agree to biopsy/resection before the first dose of IP for disease confirmation.

    Inclusion criterion 10

  3. Disease refractory to or relapsed after ≥ 2 prior lines of standard therapy, including required agents per disease subtype (e.g., anti-CD20, BTK inhibitors, chemotherapy, or ASCT if applicable).

    Inclusion criterion 11

    For patients with prior CD19-targeted therapy, confirmed CD19 positivity at screening.

    Inclusion criterion 14

    Women of childbearing potential (WOCBP) must have a negative serum pregnancy test and agree to use effective contraception during the study and for 6 months after last treatment.

    Inclusion criterion 15

    Male patients with female partners must agree to use condoms, and partners must use effective contraception, during the study and for 6 months after last treatment.

    Inclusion criterion 16

    Prior anticancer therapy-related toxicities unresolved to baseline or ≤ Grade 1 (alopecia and peripheral neuropathy excepted).

    Exclusion criterion 1

    Received prohibited treatments within 4 weeks before dosing, including high-dose corticosteroids (>20 mg prednisone equivalent daily), chemotherapy, immunosuppressive therapy, prior CAR-T or other gene/cell therapy, or T-cell engagers.

    Exclusion criterion 16

    Participation in another clinical study with investigational therapy within 3 months before dosing, or prior participation in cell/gene therapy trials.

    Exclusion criterion 17

  4. Inadequate hematologic function (ANC <1.0×10⁹/L, Hb <70 g/L, PLT <50×10⁹/L, lymphocytes ≤0.5×10⁹/L) or coagulation abnormalities (INR/APTT ≥1.5×ULN).

    Exclusion criterion 10

    Hepatic impairment (ALT/AST >2×ULN, or >3×ULN with hepatic involvement; bilirubin >2×ULN, unless Gilbert syndrome).

    Exclusion criterion 11

  5. Measurable disease per Lugano 2014 or iwCLL 2018 criteria.

    Inclusion criterion 12

    Planned radiotherapy within 6 weeks after screening (unless only non-irradiated PET-positive lesions remain eligible).

    Exclusion criterion 18

  6. History of another primary malignancy within the past 3 years, except adequately treated basal cell carcinoma, squamous cell carcinoma, or cervical carcinoma in situ.

    Exclusion criterion 5

    Active hepatitis B (HBsAg-positive with detectable HBV DNA) or hepatitis C (HCV RNA-positive) infection.

    Exclusion criterion 6

    Active or prior HIV infection.

    Exclusion criterion 7

  7. Pregnancy or breastfeeding.

    Exclusion criterion 15

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; day-to-day activity level.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07774572, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age ≥ 18 years, any gender.
  • Able to provide written informed consent.
  • Confirmed diagnosis of relapsed/refractory (R/R) CD19-positive B-cell malignancy, including:
  • Diffuse large B-cell lymphoma (DLBCL)
  • Follicular lymphoma (FL)
  • Mantle cell lymphoma (MCL)
  • Small lymphocytic lymphoma (SLL)/chronic lymphocytic leukemia (CLL)
  • Waldenström macroglobulinemia (WM)
  • Marginal zone lymphoma (MZL)
  • ECOG performance status 0 or 1.and have archival tumor biopsy tissue and pathology report from the most recent relapse, or at least one palpable superficial tumor lesion at screening, and agree to biopsy/resection before the first dose of IP for disease confirmation.
  • Disease refractory to or relapsed after ≥ 2 prior lines of standard therapy, including required agents per disease subtype (e.g., anti-CD20, BTK inhibitors, chemotherapy, or ASCT if applicable).
  • Measurable disease per Lugano 2014 or iwCLL 2018 criteria.
  • LVEF ≥ 40% by echocardiogram.
  • For patients with prior CD19-targeted therapy, confirmed CD19 positivity at screening.
  • Women of childbearing potential (WOCBP) must have a negative serum pregnancy test and agree to use effective contraception during the study and for 6 months after last treatment.
  • Male patients with female partners must agree to use condoms, and partners must use effective contraception, during the study and for 6 months after last treatment.

Exclusion Criteria:

  • Prior anticancer therapy-related toxicities unresolved to baseline or ≤ Grade 1 (alopecia and peripheral neuropathy excepted).
  • Central nervous system (CNS) involvement by lymphoma.
  • Need for urgent treatment due to tumor mass effect or spinal cord compression.
  • Known hypersensitivity to any component of IP, including mRNA/LNP-based products.
  • History of another primary malignancy within the past 3 years, except adequately treated basal cell carcinoma, squamous cell carcinoma, or cervical carcinoma in situ.
  • Active hepatitis B (HBsAg-positive with detectable HBV DNA) or hepatitis C (HCV RNA-positive) infection.
  • Active or prior HIV infection.
  • Uncontrolled active systemic infection requiring IV therapy within 1 week before dosing.
  • Active or history of acute/chronic GVHD.
  • Inadequate hematologic function (ANC <1.0×10⁹/L, Hb <70 g/L, PLT <50×10⁹/L, lymphocytes ≤0.5×10⁹/L) or coagulation abnormalities (INR/APTT ≥1.5×ULN).
  • Hepatic impairment (ALT/AST >2×ULN, or >3×ULN with hepatic involvement; bilirubin >2×ULN, unless Gilbert syndrome).
  • Renal impairment (CrCl <50 mL/min by Cockcroft-Gault).
  • Uncontrolled ischemic heart disease, NYHA Class III-IV heart failure, or baseline QTcF ≥450 ms (male) / ≥470 ms (female).
  • Severe psychiatric disorder history.
  • Pregnancy or breastfeeding.
  • Received prohibited treatments within 4 weeks before dosing, including high-dose corticosteroids (>20 mg prednisone equivalent daily), chemotherapy, immunosuppressive therapy, prior CAR-T or other gene/cell therapy, or T-cell engagers.
  • Participation in another clinical study with investigational therapy within 3 months before dosing, or prior participation in cell/gene therapy trials.
  • Planned radiotherapy within 6 weeks after screening (unless only non-irradiated PET-positive lesions remain eligible).
  • Planned allogeneic HSCT within 90 days after screening.
  • Significant comorbidities or unstable medical conditions deemed by the investigator to compromise safety or study compliance.

Quoted from ClinicalTrials.gov, NCT07774572, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07774572, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07774572